Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Masahito Nakano (principal investigator)
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07023341· Phase 3· Bayer· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289· Phase 3· Takeda· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Recruiting
Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
NCT06776549· Kagawa University· Source
Contact: Maki Otsuka (principal investigator)
Active, not recruiting
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
NCT06682572· Phase 2· Verastem, Inc.· Source
Recruiting
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
NCT06812104· Phase 1· Kyowa Kirin Co., Ltd.· Source
Contact: Masayoshi Noshiro
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Koichi Azuma, Site 0273
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Recruiting
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source
Contact: Shin NISHIO
Active, not recruiting
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
NCT06390995· Phase 1/2· Takeda· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06023862· Phase 2· Yonsei University· Source
Active, not recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299· Phase 1· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
Study of Tamibarotene in Patients With ADPKD
NCT06289998· Phase 2· Rege Nephro Co., Ltd.· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· Phase 3· Eli Lilly and Company· Source
Contact: Yohei Natsuaki (principal investigator)
Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764· Phase 3· Juntendo University· Source
Contact: Tatsuhiro Shibata
Active, not recruiting
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922· Phase 2· Haihe Biopharma Co., Ltd.· Source
Active, not recruiting
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Actelion· Source
Active, not recruiting
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778· Phase 1· Takeda· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Showing 50 of 53.